Monthly Archives: November 2009

The Case for Specialty Medicines: Is Industry Credible, or Culpable?

By William Looney | Published: November 11, 2009

What’s so special about specialty? This was the question lurking below the surface in many of the presentations at a conference hosted by Pharm Exec’s sister organization, CBI, in Philadelphia last week. Now that the blockbuster era is fading under a wave of patent expirations, big pharma is pinning its hopes on the specialty category [...]

Posted in Strategy | Tagged Biotechnology and Pharmaceuticals, business, Clinical trial, Contract Research Organizations, finance, Pharmaceutical, Products Evaluation, Research and development | Leave a comment

Roche: New Hires Needed

By Brittany Agro | Published: November 11, 2009

Cheer up, pharma, not all the news is bad! Amidst the worst national job market since the early 1980’s, Roche Pharma Research in Nutley, NJ is looking to hire. Efforts are currently underway to find scientists and support staff in areas such as screening, safety, and bioanalytics. In addition to inflammation, the Nutley operation serves as [...]

Posted in Strategy | Tagged business, Business and Economy, Consulting, Employment, Human resources, Management, Research and development, Roche | Leave a comment

Transformational Analytics Will Set You Free

By George Koroneos | Published: November 11, 2009

Guest blog by W Scott Evangelista, principal, Deloitte Consulting LLP Without committed leadership from the top of an organization, the best answers will not find the light of day, and the “my number is better than yours” issue will persist. The shackles of the past (standard reports with standard data) will inevitably bind companies to increasingly [...]

Posted in Guest Blog, Webcast, leadership | Tagged business, Competitive advantage, Consulting, Deloitte, Management, Management science, Marketing, pharmaceutical industry, Webcast | Leave a comment

The Trouble with Transparency

By George Koroneos | Published: November 6, 2009

Guest blog by Jacky Law A couple of weeks ago I attended an industry awards dinner and had an interesting conversation with an eminent doctor who shall remain nameless. The doctor in question works in a highly specialized area and frequently talks about her research at conferences around the world. She always travels first-class and has [...]

Posted in Guest Blog, Strategy | Tagged Congress, Eli Lilly, GlaxoSmithKline, Herb Kohl, Medicine, Member of Parliament, United States Senate Committee on Finance, US | Leave a comment

Merck, Schering-Plough Merger Boosts Global Profile, but Questions Linger

By Andrew Sheivachman | Published: November 5, 2009

Image via Wikipedia After Merck & Co. officially announced its $41.1 billion merger with Schering-Plough yesterday, CEO Richard Clark made it clear his company is still looking to expand through further acquisitions and mergers. According to the Wall Street Journal’s Health Blog: Clark told us today that the newly combined company is “actively looking” for biotechs to [...]

Posted in Strategy | Tagged business, Fred Hassan, Merck, Merck & Co, Pfizer, Richard Clark, Schering Plough, Wall Street Journal | 2 Comments